Business
What Novo Nordisk’s disappointing trial results mean for the obesity drug market - STAT
New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way investors view emerging candidates.
By: STAT
- Dec 22 2024
- 0
- 0 Views
The long-standing edge that Novo Nordisk has held in the obesity drug market was thrown into question Friday when the company reported results of a closely watched candidate that fell short of expect… [+877 chars]